Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Recro Pharma Q3 EPS $(0.07), Inline, Sales $18.24M Beat $18.07M Estimate

Author: Benzinga Newsdesk | November 09, 2021 06:24pm

Recro Pharma (NASDAQ:REPH) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 22.22 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $18.24 million which beat the analyst consensus estimate of $18.07 million by 0.92 percent. This is a 5.44 percent decrease over sales of $19.29 million the same period last year.

Posted In: REPH